Lowest Price Guaranteed
Pages
178
Last Updated
August 2026
View Count
13912
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of CD47 targeting therapeutics market and its likely evolution in the short to mid-long term.
Chapter 3 provides a general introduction to the CD47 gene and associated pathways in the human cells. In addition, it features information on the historical timeline and different areas of applications that have been identified. It also features an elaborate description of pathways that are activated during the phagocytosis process. Further, it highlights the potential side effects, clinical features and therapeutic benefits of targeting CD47 / SIRPAα pathways for the treatment of various oncological indications.
Chapter 4 includes a detailed analysis of the current market landscape of CD47 targeting therapeutics, along with information on several parameters, such as phase of development (clinical and preclinical), target disease indication(s), therapeutic area (hematological malignancies, dermatological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological and small molecules), type of therapy (monotherapies, and combination therapies), type of biologic (monoclonal antibody, bi-specific antibody, recombinant fusion protein, peptide, antibodies, bi-functional fusion protein, fusion protein, protein), SIRPA toll-like receptor agonist antibody conjugate (TRAAC)), route of administration (intravenous, subcutaneous, and intraperitoneal), and special drug designation awarded (if any).
Chapter 5 highlights the companies engaged in the development of CD-47 targeting therapeutics, along with information on their year of establishment, company size (in terms of employee count) and location of respective headquarters.
Chapter 6 features elaborate profiles of key players engaged in the development of CD47 targeting therapeutics. Each profile features a brief overview of the company, on its drug candidates, financial information (if available), recent development and an informed future outlook.
Chapter 7 includes a detailed analysis of more than 70 completed, ongoing and planned clinical trials of various CD47 targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, leading sponsors / collaborators, most active players (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials.
Chapter 8 includes a detailed analysis of close to 600 peer-reviewed, scientific articles related to research on CD47 targeting therapies over the past few years, based on several relevant parameters, such as year of publication, type of publication, therapeutic area, target indication and key journals (in terms of number of articles published).
Chapter 9 provides an analysis of the recent partnerships inked between various players engaged in the development of CD47 targeting therapies, during the period 2016-2021, based on several relevant parameters such as number of partnership instances, type of partnerships, regional distribution (continent and country-wise) and most active players (in terms of number of partnership instances).
Chapter 10 includes a detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.
Chapter 11 provides an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this domain, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of CD47-based therapies.
Chapter 12 provides an analysis highlighting various social media trends (Twitter), along with information on prominent accounts, popular keywords and hashtags, as well as year and number of tweets added by players engaged in the development of CD47-based therapies.
Chapter 13 provides an analysis of the companies engaged within this domain, featuring a 3-D bubble chart analysis of different peer groups (North America, Europe and, Asia-Pacific), based on various parameters, such as pipeline strength, portfolio diversity and portfolio strength.
Chapter 14 includes an analysis of big pharma players engaged in this domain, featuring a wind rose chart based on several relevant parameters, such as number of therapeutics under development, phase of development, line of therapy, number of indications targeted and years of experience.
Chapter 15 includes an analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in the development of CD47 based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of indications targeted, amount raised, number of investors, type of funding and number of deals inked.
Chapter 16 presents an insightful market forecast analysis, highlighting the likely growth of CD47 targeting therapeutics market till 2035. We have segmented market across [A] target disease indication (acute myeloid leukemias, CD20 positive non-hodgkin lymphoma, colorectal cancers, diffuse large b-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral muscositis, small cell lung cancers), [B] type of molecule (biologics and small molecule), [C] key players and [D] key geographical regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel).
Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Target Protein
4.2.3. Analysis by Type of Biologic
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Type of Molecule and Route of Administration
4.2.6. Analysis by Line of Treatment
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Target Indication
4.2.10. Analysis by Type of Therapy
4.3. CD-47 Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Pipeline Candidates
4.3.5. Analysis by Phase of Development
4.3.6 Analysis by Regional Strength
4.3.7. Analysis by Company Size and Location of Headquarters
4.3.8. Analysis by Year of Establishment, Company Size and Location of Headquarters
5. COMPANY PROFILES
5.1. Abpro
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. ALX Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Apmonia Therapeutics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Arch Oncology
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Aurigene
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Bristol Myers Squibb
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. EpicentRx
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Forty Seven
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. ImmuneOncia Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. ImmuneOnco Biopharmaceuticals
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Innovent Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. KAHR Medical
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook
5.13. Light Chain Bioscience
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook
5.14. Morphiex
5.14.1. Company Overview
5.14.2. Financial Information
5.14.3. Product Portfolio
5.14.4. Recent Developments and Future Outlook
5.15. Trillium Therapeutics
5.15.1. Company Overview
5.15.2. Financial Information
5.15.3. Product Portfolio
5.15.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CD-47 Targeting Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Registration Year
6.3.3. Analysis by Trial Status and Trial Registration Year
6.3.4. Analysis by Number of Patients Enrolled and Phase of Development
6.3.5. Analysis by Type of Sponsor
6.3.6. Analysis by Target Patient Group
6.3.7. Analysis by Study Type
6.3.8. Analysis by Type of Masking
6.3.9. Analysis by Type of Interventional Model
6.3.10. Analysis by Primary Purpose of Trial
6.3.11. Analysis of Enrolled Patient Population by Geography
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. CD-47 Therapeutics: List of Publications
7.3.1. Analysis by Year of Publication
7.3.2. Analysis by Type of Publication
7.3.3. Analysis by Therapeutic Area
7.3.4. Analysis by Target Indication
7.3.5. Analysis by Affiliation of First Author
7.3.6. Leading Players: Analysis by Number of Publications
7.3.7. Key Journals: Analysis by Number of Publications
8. PARTNERSHIPS AND COLLABORATIONS
8.1. CD-47 Therapeutics: List of Partnerships and Collaborations
8.1.1 Cumulative Analysis by Year, 2015-2021
8.1.1. Analysis by Type of Partnership
8.1.2. Analysis by Year and Type of Partnership
8.1.3. Analysis by Type of Partner
8.1.4. Analysis by Year by Type of Partner
8.1.5. Analysis by Type of Partner andType of Partnership
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Region (Continent-wise)
8.1.7.1 Intercontinental and Intracontinental Agreements
8.1.8. Analysis by Region (Country-wise)
8.1.8.1 Local and International Agreements
9. FUNDING AND INVESTMENTS
9.1. CD-47 Therapeutics: List of Funding and Investments
9.1.1. Cumulative Analysis of Funding Instances by Year, 2015–2021
9.1.5. Analysis of Number of Instances by Type of Funding
9.1.2. Analysis of Instances by Year and Type of Funding, 2015–2021
9.1.3. Cumulative Analysis of Amount Invested by Year, 2015–2021
9.1.4. Analysis of Amount Invested by Year and Type of Funding, 2015–2021
9.1.6. Analysis of Amount Invested by Type of Funding
9.1.7. Analysis of Instances by Geography
9.1.8. Analysis of Total Amount Invested by Geography
9.1.9. Most Active Players: Analysis by Number of Instances
9.1.10. Most Active Players: Analysis by Amount Raised
9.1.11. Most Active Investors: Analysis by Number of Funding Instances,
10. KEY OPINION LEADERS
10.1. CD-47 Therapeutics: List of Key Opinion Leaders
10.1.1. Analysis by Type of Current Organization
10.1.2. Analysis by Geography
10.1.2.1. Analysis by Region (Continent-wise Distribution)
10.1.2.2. Analysis by Region (Country-wise Distribution)
10.1.3. Analysis by Number of Investigators and Current Organization
10.1.4. Analysis by Qualification of KOL
10.1.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
10.1.6. Comparison of Roots Analysis Score v/s Third Party Score
10.1.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
10.1.8. Analysis by Region
10.1.9. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
11. EMERGING TRENDS ON SOCIAL MEDIA
11.1. Chapter Overview
11.2. CD-47 Therapeutics: Trends on Twitter
11.2.1. Historical Trend in Volume of Tweets
11.2.2. Trending Words / Phrases on Twitter
11.2.3. Most Popular Drugs on Twitter
11.2.4. Most Prolific Authors on Twitter
11.2.5. Most Popular Indications
12. COMPANY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters
12.3. CD-47 Therapy Developers
12.3.1. Peer Group 1: Players based in North America
12.3.2. Peer Group 2: Players based in Europe
12.3.3. Peer Group 3: Players based in Asia-Pacific
13. BIG PHARMA PLAYERS
13.1. Chapter Overview
13.2. Methodology and Key Parameters
13.2.1. Analysis by Pipeline Strength
13.2.2. Analysis by Funding and Investments
13.2.3. Analysis by Partnerships
13.2.4. Analysis by Clinical Trials
13.2.5. Summary of Big Pharma Activity
14. START-UP HEALTH INDEXING
14.1. Chapter Overview
14.2. Start-ups Focused on CD-47 Targeting Therapeutics
14.3. Methodology and Key Parameters
14.4.1 Analysis by Location of Headquarters
14.2.3. Analysis by Pipeline Maturity
14.2.4. Analysis by Pipeline Strength
14.2.5. Analysis by Indication Diversity
14.2.6. Analysis by Capital Accrued through Investments
14.2.7. Analysis by Number of Investors
14.2.8. Analysis by Partnership Activity
14.2.9. Start-ups Health Indexing: Roots Analysis Perspective
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global CD-47 Targeting Therapeutics Market, 2021-2035
15.5. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Target Indication
15.5.1. CD-47 Targeting Therapeutics Market for Acute Myeloid Leukemia
15.5.2. CD-47 Targeting Therapeutics Market for Colorectal Neoplasms
15.5.3. CD-47 Targeting Therapeutics Market for Diffuse-Large Cell Lymphoma
15.5.4. CD-47 Targeting Therapeutics Market for Myelodysplastic Syndromes
15.5.5. CD-47 Targeting Therapeutics Market for Non-Hodgkin Lymphoma
15.5.6. CD-47 Targeting Therapeutics Market for Non-Small Cell Lung Cancer
15.5.7. CD-47 Targeting Therapeutics Market for Oral Muscositis
15.5.8. CD-47 Targeting Therapeutics Market for Ovarian Epithelial Cancer
15.5.9. CD-47 Targeting Therapeutics Market for Small Cell Lung Cancer
15.6. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Type of Molecule
15.6.1. CD-47 Targeting Therapeutics Market for Biologics
15.6.2. CD-47 Targeting Therapeutics Market for Small Molecules
15.7. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Geography
15.7.1. CD-47 Targeting Therapeutics Market in the US
15.7.2. CD-47 Targeting Therapeutics Market in France
15.7.3. CD-47 Targeting Therapeutics Market in Germany
15.7.4. CD-47 Targeting Therapeutics Market in Italy
15.7.5. CD-47 Targeting Therapeutics Market in Spain
15.7.6. CD-47 Targeting Therapeutics Market in UK
15.7.7. CD-47 Targeting Therapeutics Market in Australia
15.7.8. CD-47 Targeting Therapeutics Market in China
15.7.9. CD-47 Targeting Therapeutics Market in India
15.7.10. CD-47 Targeting Therapeutics Market in Israel
15.8. Drug-wise Sales Forecast
15.8.1. CPO-127 (Conjupro biotherapeutics)
15.8.1.1. Target Patient Population
15.8.1.2. Value Creation Analysis
15.8.2. DSP-107 (KAHR Medical)
15.8.2.1. Target Patient Population
15.8.2.2. Value Creation Analysis
15.8.3. IBI188 (Innovent Biologics)
15.8.3.1. Target Patient Population
15.8.3.2. Value Creation Analysis
15.8.4. Magrolimab (Forty Seven)
15.8.4.1. Target Patient Population
15.8.4.2. Value Creation Analysis
15.8.5. RRX-001 (EpicentRx)
15.8.5.1. Target Patient Population
15.8.5.2. Value Creation Analysis
16. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS
Table 4.1. List of CD-47 Targeting Therapeutics
Table 4.1. List of CD-47 Targeting Therapeutic Developers
Table 6.1. CD-47 Targeted Therapeutics: List of Clinical Trials
Table 7.1. CD-47 Targeted Therapeutics: List of Publications
Table 8.1. CD-47 Targeted Therapeutics: List of Partnerships and Collaborations
Table 9.1. CD-47 Targeted Therapeutics: List of Funding and Investments
Table 10.1 CD-47 Targeted Therapeutics: List of Key Opinion Leaders
Table 11.1 CD-47 Targeted Therapeutics: List of Tweets
Table 14.1 CD-47 Targeted Therapeutics: List of Start-ups
Table 15.1 CD-47 Targeted Therapeutics: List of Forecasted Drugs
Please reach out to our team for the details.